Search Results - "Zhou, Cathy"

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 by Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Tedeschi, Alessandra, Bairey, Osnat, Bartlett, Nancy L, Burger, Jan A, Hillmen, Peter, Coutre, Steven, Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Li, Jianyong, Simpson, David, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Styles, Lori, James, Danelle, Kipps, Thomas J, Ghia, Paolo

“…Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of…”
Get full text

Long-read Ribo-STAMP simultaneously measures transcription and translation with isoform resolution by Jagannatha, Pratibha, Tankka, Alexandra T, Lorenz, Daniel A, Yu, Tao, Yee, Brian A, Brannan, Kristopher W, Zhou, Catherine Jiarui, Underwood, Jason G, Yeo, Gene W

“…Transcription and translation are intertwined processes where mRNA isoforms are crucial intermediaries. However, methodological limitations in analyzing…”
Get full text

Functional Adrenal Collision Tumor in a Patient with Cushing’s Syndrome by Zhou, Cathy, Campbell, Michael J., Fananapazir, Ghaneh

“…Adrenal collision tumors are rare and produce unique diagnostic challenges for clinicians. We report the case of a 45-year-old woman with obesity and diabetes…”
Get full text

Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma by Coutre, Steven, Tedeschi, Alessandra, Robak, Tadeusz, Barr, Paul M, Owen, Carolyn, Bairey, Osnat, Burger, Jan, Zhou, Cathy, Styles, Lori, James, Danelle F, Kipps, Thomas J

Get full text

Skip and save: utility of pelvic x-rays in the initial evaluation of blunt trauma patients by Soto, Jose Raul, M.D., M.P.H, Zhou, Cathy, M.D, Hu, David, M.D, Arazoza, Antonio C., M.D, Dunn, Ernest, M.D, Sladek, Phillip, M.D

“…Abstract Background The cost of medical care is an area of major emphasis in the current healthcare environment. Medical providers have a significant role in…”
Get full text

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors by Zhou, Cathy, Yuan, Zilong, Ma, Weijie, Qi, Lihong, Mahavongtrakul, Angelique, Li, Ying, Li, Hong, Gong, Jay, Fan, Reggie R, Li, Jin, Molmen, Michael, Clark, Travis A, Pavlick, Dean, Frampton, Garrett M, Forcier, Brady, Moore, Elizabeth H, Shelton, David K, Cooke, Matthew, Ali, Siraj M, Miller, Vincent A, Gregg, Jeffrey P, Stephens, Philip J, Li, Tianhong

“…This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced…”
Get full text

P617: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY by Ghia, Paolo, Allan, John, Siddiqi, Tanya, Wierda, William G., Tam, Constantine, Moreno, Carol, Tedeschi, Alessandra, Szafer‐Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, Jim, Szoke, Anita, Barr, Paul M.

Get full text

Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics by Zhou, Cathy, Foster, Brent, Hagge, Rosalie, Foster, Cameron, Lenchik, Leon, Chaudhari, Abhijit J., Boutin, Robert D.

“…Objective 18 F-FDG PET is widely used to accurately stage numerous types of cancers. Although 18 F-FDG PET/CT features of tumors aid in predicting patient…”
Get full text

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial by Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Samoilova, Olga, Novak, Jan, Ben-Yehuda, Dina, Strugov, Vladimir, Gill, Devinder, Gribben, John G, Hsu, Emily, Lih, Chih-Jian, Zhou, Cathy, Clow, Fong, James, Danelle F, Styles, Lori, Flinn, Ian W

“…Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments…”
Get full text

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study by Wierda, William G, Allan, John N, Siddiqi, Tanya, Kipps, Thomas J, Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C, Kuss, Bryone J, Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M, Flinn, Ian, Pak, Yvonne, Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P, James, Danelle F, Ghia, Paolo, Tam, Constantine S

“…CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of…”
Get full text

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort by Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Jacobs, Ryan, Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Trentin, Livio, Bannerji, Rajat, Jackson, Sharon, Kuss, Bryone J., Moreno, Carol, Szafer-Glusman, Edith, Russell, Kristin, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Wierda, William G., Ghia, Paolo

“…CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from…”
Get full text

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib by Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan

“…Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In…”
Get full text

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia by Barr, Paul M., Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A., Hillmen, Peter, Coutre, Steve E., Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-Yong, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J., Ghia, Paolo

“…We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted…”
Get full text

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study by Ghia, Paolo, Wierda, William G., Barr, Paul M., Kipps, Thomas J., Siddiqi, Tanya, Allan, John N., Hunter, Zoë, Zhou, Cathy, Szoke, Anita, Dean, James P., Tam, Constantine S.

“…Background:CAPTIVATE (PCYC-1142) is a multicenter phase 2 study of ibrutinib + venetoclax as first-line treatment for CLL/SLL in 2 cohorts: minimal residual…”
Get full text

Abstract 4350: Characterization of PUF60 splicing activity that is essential for the survival of triple negative breast cancer by Tankka, Alexandra, Gomberg, Trent, Zhou, Cathy, Pham, Vivian, Yeo, Gene

“…Abstract Alternative splicing driven by RNA-binding proteins (RBPs) plays a significant role in TNBC, however, pharmacological modulators of core spliceosomal…”
Get full text

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study by Barr, Paul M., Allan, John N., Siddiqi, Tanya, Wierda, William G., Tam, Constantine Si Lun, Moreno, Carolina D., Tedeschi, Alessandra, Szafer-Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, James P., Szoke, Anita, Ghia, Paolo

“…7535 Background: CAPTIVATE (PCYC-1142) is a multicenter phase 2 study of first-line ibrutinib (I) + venetoclax (V) in CLL/SLL. Follow-up results from the fixed…”
Get full text

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia by Allan, John N, Flinn, Ian W, Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S, Kipps, Thomas J, Barr, Paul M, Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C, Jacobs, Ryan, Kuss, Bryone J, Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G

“…The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided…”
Get full text

Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study by Wierda, William G., Jacobs, Ryan, Barr, Paul M., Allan, John N., Siddiqi, Tanya, Tedeschi, Alessandra, Kipps, Thomas J., O'Brien, Susan Mary, Badoux, Xavier C., Visentin, Andrea, Lasica, Masa, Carney, Dennis, Elinder Camburn, Anna, De La Serna Torroba, Javier, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Dean, James P., Ghia, Paolo, Tam, Constantine S.

“…7009 Background: The phase 2 CAPTIVATE study evaluated first-line ibrutinib (Ibr) + venetoclax (Ven) for CLL/SLL in 2 cohorts: minimal residual disease…”
Get full text

Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre by Zhou, Cathy, Urbauer, Diana L., Fellman, Bryan M., Tamboli, Pheroze, Zhang, Miao, Matin, Surena F., Wood, Christopher G., Karam, Jose A.

“…Objective To describe the presentation, treatment and outcomes of patients with metastatic tumours to the kidney treated at a tertiary referral centre…”
Get full text

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Coutré, Steven E, Furman, Richard R, Flinn, Ian W, Burger, Jan A, Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F, Byrd, John C, O'Brien, Susan

“…Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and…”
Get full text